Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | HRH2 | P25021 | 2/20 | 0.33 |
| ▸ | HRH1 | P35367 | 2/20 | 0.33 |
| ▸ | ELANE | P08246 | 1/20 | 0.33 |
| ▸ | SCN4A | P35499 | 1/20 | 0.30 |
| ▸ | NOS3 | P29474 | 1/20 | 0.30 |
| ▸ | NOS1 | P29475 | 1/20 | 0.30 |
| ▸ | NOS2 | P35228 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL743847 | 0.91 | ELANE (0.42) | HRH2HRH1ELANESCN4ANOS3 | |
| SCHEMBL7289268 | 0.88 | HTR2C (0.38) | CYP2D6HRH2HRH1ELANESCN4A | |
| SCHEMBL747207 | 0.87 | CTSK (0.38) | MEN1CYP2D6KMT2AHRH2HRH1 | |
| SCHEMBL28289372 | 0.80 | CTSC (0.38) | — | |
| SCHEMBL7408036 | 0.77 | HSD11B1 (0.47) | — | |
| SCHEMBL11716695 | 0.76 | MEN1 (0.62) | MEN1CYP2D6KMT2A | |
| SCHEMBL232050 | 0.75 | NPC1 (0.47) | MEN1CYP2D6KMT2A | |
| SCHEMBL11710930 | 0.73 | CYP2D6 (0.50) | MEN1CYP2D6KMT2A | |
| SCHEMBL2989814 | 0.73 | PLK1 (0.44) | MEN1CYP2D6KMT2A | |
| SCHEMBL5214996 | 0.72 | SRD5A2 (0.55) | MEN1CYP2D6KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6515013-B2 | For diseases or conditions caused by or exacerbated by histamine-3 receptor activity | ABBOTT LABORATORIES | 2003-02-04 | — | — | US | disclosed |
| US-20020035103-A1 | 1,3-Disubstituted and 1,3,3-trisubstituted pyrrolidines as histamine-3 receptor ligands and their therapeutic applications | ABBVIE INC. | 2002-03-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020035103-A1 | 1,3-Disubstituted and 1,3,3-trisubstituted pyrrolidines as histamine-3 receptor ligands and their therapeutic applications | HRH3, HRH4, HRH1 | MEN1 1992/4885CYP2D6 1627/4885KMT2A 2791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.